Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Neoplasia may develop in patients with malignant hematologic disorders, during remission after radio and/or chemotherapy. A multifactorial origin related to therapy may be postulated. From 1978 to 1987, among 142 patients with malignant hematologic disorders (Hodgkin lymphoma 33, non-Hodgkin lymphoma 51, Multiple Myeloma 35 and Chronic Myeloid Leukemia 31) we observed 3 patients developing another neoplasia. An additional patient with acute non-lymphatic leukemia had been submitted to chemotherapy for gastric cancer. Four other patients with double neoplasia, one of them a hematologic one, had not been submitted to chemotherapy. The lack of national registries for neoplastic diseases precludes an estimation of the odd ratios involved in our findings.
 ...
PMID:[Second neoplasms in malignant hematologic disorders. Experience from 1978 to 1987]. 196 10

Although cancer mortality in young adults accounts for only a small proportion of all cancer deaths, it is important since it provides useful indications of the most likely future trends, and relevant information on the role of exposure to specific, or newer, carcinogens. We, therefore, analysed trends in cancer mortality between 1955 and 1985 among Italian men and women aged 20-44 years. In those three decades, overall cancer mortality declined steadily, by 27% in young women (from 33.8 to 24.7/100,000, world standard) but only by 3% (from 27.3 to 26.4/100,000) among men. The decline for men, however, was 16% from the peak rate of 31.5 reached in 1970-1974. The major underlying component causing the different trends in the two sexes was lung and other tobacco-related neoplasms, which had been considerably on the increase in young men up to the early 1970s, and levelled-off thereafter, while showing no appreciable change in women. The falls were about 50% for stomach cancer in both sexes, and over 80% for cervical cancer. A clear impact of improved treatment was reflected in the substantial declines in Hodgkin's disease, of testicular cancer in the last decade and, possibly, in the favourable trends in cancers of the breast, bone, brain and leukemias over the most recent calendar periods. Only two sites showed appreciable and persisting upward trends: oral cavity in men and skin melanoma in both sexes. They therefore constitute priorities for intervention in the near future.
 ...
PMID:Cancer mortality in young adults: Italy 1955-1985. 232 66

Data from the national tumor registry of Costa Rica for the years 1979-1983 have been used to calculate incidence rates for the major cancer sites by age, sex, urban-rural residence, and geographic region. Recent trends in mortality rates are also presented. Results are compared with data from elsewhere in Latin America, U.S.A., Europe, and Japan. Stomach cancer is the most frequent neoplasm in Costa Rica; although rates are declining, they are second only to those observed in Japan. There are marked variations in risk by region, suggesting important environmental influences in etiology. The cervix is the major female site; rates are declining in young women, probably due to the introduction of screening programs, although these do not seem to account for the geographic variations in invasive cancer incidence. Breast and prostate cancer show moderate rates, while those for colon and rectum cancer are low; increases in mortality rates for these sites are small, and involve mainly the older age groups. In contrast, rates of lung cancer are increasing dramatically in both sexes. In the childhood age group, very high incidence rates are observed for two neoplasms: Hodgkin's disease and acute lymphocytic leukemia.
 ...
PMID:Cancer in Costa Rica. 291 Apr 91

The mortality experienced by a cohort of 36,691 rubber workers during 1946-85 has been investigated. These workers were all male operatives first employed in any one of the 13 participating factories in 1946-60; all had worked continuously in the industry for a minimum period of one year. Compared with the general population, statistically significant excesses relating to cancer mortality were found for cancer of the pharynx (E = 20.2, O = 30, SMR = 149), oesophagus (E = 87.6, O = 107, SMR = 122), stomach (E = 316.5, O = 359, SMR = 113), lung (E = 1219.2, O = 1592, SMR = 131), and all neoplasms (E = 2965.6, O = 3344, SMR = 113). Statistically significant deficits were found for cancer of the prostate. (E = 128.2, O = 91, SMR = 71), testis (E = 11.0, O = 4, SMR = 36), and Hodgkin's disease (E = 26.9, O = 16, SMR = 59). Involvement of occupational exposures was assessed by the method of regression models and life tables (RMLT). This method was used to compare the duration of employment in the industry, the duration in "dust exposed" jobs, and the duration in "fume and/or solvent exposed" jobs of those dying from causes of interest with those of all matching survivors. Positive associations (approaching formal levels of statistical significance) were found only for cancers of the stomach and the lung. The results of the RMLT analysis are independent of those from the SMR analysis, and the study continues to provide limited evidence of a causal association between the risks of stomach cancer and dust exposures, and the risks of lung cancer and fume or solvent exposures in the rubber industry during the period under study.
 ...
PMID:Mortality in the British rubber industry 1946-85. 292 Jan 37

Epirubicin (4'-epidoxorubicin) is an antineoplastic agent derived from doxorubicin. The compounds differ in the configuration of the hydroxyl group at the 4' position. Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle. Epirubicin is administered by intravenous (IV) injection. It is metabolized by the liver and primarily eliminated in the bile. About 10% of the drug is eliminated in the urine. Dosage adjustments are recommended for patients with liver metastases or elevated liver function tests. The elimination half-life of epirubicin is 30 to 40 hours. Clinical studies indicate activity in breast cancer, non-Hodgkin's lymphomas, ovarian cancer, soft-tissue sarcomas, and pancreatic cancer. There is also evidence of activity against gastric cancer, small-cell lung cancer, and acute leukemia. Epirubicin has limited activity as a single agent against head and neck tumors or non-small-cell lung cancer, but may be beneficial in combination with other agents. The overall activity of epirubicin appears to be comparable with that of doxorubicin. However, more studies are needed to define its role in combination chemotherapeutic regimens. The acute dose-limiting toxicity of epirubicin is myelosuppression. Nausea, vomiting, and alopecia are also common. Epirubicin may cause transient cardiac arrhythmias and alterations of the electrocardiogram. Chronic therapy is limited, but available data indicate that epirubicin can be administered in higher cumulative doses than doxorubicin before cardiotoxicity limits further therapy.
 ...
PMID:Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. 300 21

The risk of cancer associated with a broad range of organ doses was estimated in an international study of women with cervical cancer. Among 150,000 patients reported to one of 19 population-based cancer registries or treated in any of 20 oncology clinics, 4188 women with second cancers and 6880 matched controls were selected for detailed study. Radiation doses for selected organs were reconstructed for each patient on the basis of her original radiotherapy records. Very high doses, on the order of several hundred gray, were found to increase the risk of cancers of the bladder [relative risk (RR) = 4.0], rectum (RR = 1.8), vagina (RR = 2.7), and possibly bone (RR = 1.3), uterine corpus (RR = 1.3), cecum (RR = 1.5), and non-Hodgkin's lymphoma (RR = 2.5). For all female genital cancers taken together, a sharp dose-response gradient was observed, reaching fivefold for doses more than 150 Gy. Several gray increased the risk of stomach cancer (RR = 2.1) and leukemia (RR = 2.0). Although cancer of the pancreas was elevated, there was no evidence of a dose-dependent risk. Cancer of the kidney was significantly increased among 15-year survivors. A nonsignificant twofold risk of radiogenic thyroid cancer was observed following an average dose of only 0.11 Gy. Breast cancer was not increased overall, despite an average dose of 0.31 Gy and 953 cases available for evaluation (RR = 0.9); there was, however, a weak suggestion of a dose response among women whose ovaries had been surgically removed. Doses greater than 6 Gy to the ovaries reduced breast cancer risk by 44%. A significant deficit of ovarian cancer was observed within 5 years of radiotherapy; in contrast, a dose response was suggested among 10-year survivors. Radiation was not found to increase the overall risk of cancers of the small intestine, colon, ovary, vulva, connective tissue, breast, Hodgkin's disease, multiple myeloma, or chronic lymphocytic leukemia. For most cancers associated with radiation, risks were highest among long-term survivors and appeared concentrated among women irradiated at relatively younger ages.
 ...
PMID:Radiation dose and second cancer risk in patients treated for cancer of the cervix. 318 29

A case of a 69 years old male patient with primary malignant non-Hodgkin lymphoma is presented. The disease resembled clinically, roentgenologically and endoscopically gastric cancer. The diagnosis was proved by histologic examination which revealed lymphoblast sarcoma with significant malignancy. The etiopathogenesis, clinical, diagnostic, prognostic and therapeutic problems of malignant non-Hodgkin gastric lymphoma are discussed.
 ...
PMID:[Primary malignant non-Hodgkin's lymphoma of the stomach]. 320 99

Sweden has had cancer and population registers since 1958, indicating an increasing total age-adjusted cancer incidence. The incidence of liver, prostate and urinary tract cancer, as well as of melanoma and lymphoma, is increasing, whereas that of stomach cancer and Hodgkin's lymphoma is decreasing. National public recommendations by the nutrition and exercise committee of the National Board of Health and Welfare to reduce fat, salt, energy and sugar intake and to increase fiber intake and exercise have existed for 20 yr. The purpose was initially to prevent cardiovascular diseases, later also to prevent breast and prostatic cancer. Since the 1970s, Swedish women have been offered systematic gynecological health checks, resulting in a reduced incidence and mortality of cervix carcinoma. Local Swedish studies suggest that systematic mammography, which is now recommended on a national basis, can reduce breast cancer mortality by 30%. It is estimated that between 300 and 1100 cases of bronchopulmonary carcinoma are partly caused by a dwelling environment with over 400 Bq radon m-3. General rebuilding of the 40,000 houses concerned is at present being considered.
 ...
PMID:Cancer risks and cancer prevention in Sweden. 332 89

We calculated 5-year crude and relative survival rates, by age and sex, for patients in Alberta in whom cancer was diagnosed between 1974 and 1978. Cancers with low overall 5-year relative survival rates (less than 35%) included stomach cancer, cancer of the pancreas, lung cancer, brain cancer, multiple myeloma and myeloid leukemia. Cancers with high overall 5-year relative survival rates (more than 70%) included melanoma, breast cancer, cancer of the uterus, cancer of the bladder and Hodgkin's disease. Five-year relative survival rates were generally lower in the highest age group (75 years or more). A strong inverse relation between age and survival was noted for brain cancer, non-Hodgkin's lymphoma, Hodgkin's disease and myeloid leukemia.
 ...
PMID:Survival rates among patients with cancer in Alberta in 1974-78. 337 May 94

Five-year relative case-survival rates for all cancers collectively are similar in South Australia (49%) and the United States (50%). This suggests that outcomes of cancer treatment do not vary appreciably between the two populations. There is an indication of higher survival rates in South Australia for melanoma, Hodgkin's disease, multiple myeloma and gastric cancer, but lower survival rates for cancers of the thyroid, corpus uteri, prostate, colon, kidney and lung. The differences in point estimates of the rates were most conspicuous for Hodgkin's disease, multiple myeloma and prostatic cancer. The reasons for a cautious interpretation of these findings are discussed and some possible explanations are suggested. South Australian data point to an upward trend in survival rates between the diagnostic periods 1977-1980 and 1981-1985 for patients with Hodgkin's disease, diffuse large-cell lymphomas, melanomas and cancers of the prostate and rectum.
 ...
PMID:Cancer case-survival rates for South Australia: a comparison with US rates and a preliminary investigation of time trends. 337 24


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>